Gloria M. Palomo studied Biochemistry at Universidad Autónoma de Madrid. She is an enthusiast of Neuroscience, Biotechnology and Molecular Biology, which were the topics followed in her postgraduate studies. During her PhD studies at Universidad Autónoma de Madrid, Gloria focused her work on a rare neurodegenerative disease, Friedreich´s ataxia, where she uncovered a new mechanism underlying neuronal cell death, a common feature of this pathology and contributed to the proof of concept studies for the gene therapy approach in this disease. During her postdoc at Weill Cornell Medicine in New York, she worked on ALS and the pathological mechanisms of the disease associated with mitochondria quality control, especially mitophagy which is the selective degradation of mitochondria through autophagy pathways. Gloria M. Palomo is currently non-clinical assessor in the Advanced Therapies and Vaccines Area (Preclinical Division) at the Spanish Agency for Medicinal Products and Medical Devices, and the member from Spain/AEMPS Representative of the Committee for Orphan Medicinal Products of EMA.